Clinical Trial

First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 19, 2025 (before its estimated January 26, 2026 completion). Its status may not reflect the trial's current state.
Summary
Phase 1 trial to evaluate the Safety and Immunogenicity of Inventprise's (IVT) Shigella-04 in Healthy Young Adults
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-25.
Trial Details
NCT Number NCT07205926
Lead Sponsor Inventprise Inc.
Conditions Shigella, Diarrhea
Enrollment 60 participants
Start Date 2025-10-09
Primary Completion 2026-01-26 (estimated)
Study Completion 2026-08-21 (estimated)
Updated on ClinicalTrials.gov 2025-11-19